Changes to Taxus manufacturing
This article was originally published in The Gray Sheet
Executive Summary
FDA approves special PMA supplement May 5 for Boston Scientific to modify the laser bonding process used to unite the drug-eluting stent's delivery catheter and balloon prior to packaging. The move responds to physician complaints about the balloon not deflating properly or sticking to the stent coating during removal (1"The Gray Sheet" May 3, 2004, In Brief). A recall will not be initiated, the company says, claiming the best way to avoid potential problems with existing stents is to follow the instructions for use, specifically concerning inflation and deflation timing and pressure. Boston Scientific attributes the issues to physicians being unfamiliar with the system. FDA does not plan to formally address the issue; however, the agency notes its will provide communications if further problems arise...
You may also be interested in...
Boston Scientific’s “sticky balloons”
CFO Larry Best characterizes as "a very small issue" reports that catheter balloons are sticking or not deflating during removal afterTaxus drug-eluting stent deployment (1"The Gray Sheet" May 10, 2004, In Brief). "With every launch, there are situations reported where the device did not work as well as expected. We have had [a] very, very small occurrence of what we call 'sticky balloons.'" Speaking at the Banc of America Securities Health Care Conference in Las Vegas May 19, Best added that "why it occurs, to be honest with you, we do not know." Taxus generated $78 mil. in U.S. sales during the 10 working days from May 1-14, accounting for over 70% of U.S. DES sales, the firm claims...
FDA stays tuned to Taxus adverse events
Agency pledges to keep the public apprised of complaints related to the Boston Scientific paclitaxel-eluting stent, but says collected data detailing 28 Taxus incidents to date are insufficient to justify a formal solicitation similar to last October's "web notification" about J&J/Cordis' Cypher thrombosis rates. Some physicians have reported that the Taxus delivery system resists extraction after stent deployment, possibly due to improper balloon deflation. The incident rate is about 11.8 complaints per 1,000 used, Boston Scientific says, attributing the problems to physicians unfamiliar with the system (1"The Gray Sheet" April 26, 2004, p. 5)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”